Supplemental Appendix

A phase 2, multicenter, open-label trial (ACE-LY-003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma

Paolo Strati,1 Morton Coleman,2 Rebecca Champion,3 Shuo Ma,4 Caterina Patti,5 Moshe Y. Levy,6 Izidore S. Lossos,7 Praveen Ramakrishnan Geethakumari,8 Selay Lam,9 Roser Calvo,10 Kara Higgins,11 Lihua E. Budde12

1The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 2Clinical Research Alliance/Weill Cornell Medicine, Inc, New York, NY, USA; 3Norton Cancer Institute, Louisville, KY, USA; 4Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA; 5A.O.O.R. Villa Sofia-Cervello, U. O. C. Oncoematologia, Palermo, Italy; 6Baylor University Medical Center, Dallas, TX, USA; 7University of Miami–Miller School of Medicine, Miami, FL, USA; 8Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA; 9London Health Sciences Centre, London, Ontario, Canada; 10AstraZeneca, Gaithersburg, MD, USA; 11AstraZeneca, South San Francisco, CA, USA; 12City Of Hope National Medical Center, Duarte, CA, USA
Supplemental Figures

Supplemental Figure 1. Best Percent Change in Sum of Product Diameters. Best percentage change from baseline in target lesion sum of product diameters by (A) best overall response and (B) MZL subtype. MZL, marginal zone lymphoma; SPD, sum of product diameters.
Supplemental Figure 2. Swimmer Plot for Response Assessment. Swimmer plot for response assessment in all treated patients. ACP, acalabrutinib; CR, complete response; EOT, end of treatment; MZL, marginal zone lymphoma; PD, progressive disease; PR, partial response; SD, stable disease.
**Supplemental Figure 3. MRD Results.** Swimmer plot for MRD results for six evaluable patients. CR, complete response; MRD, minimal residual disease; PD, progressive disease; PR, partial response; SD, stable disease.